News

The UK’s COVID-19 vaccination programme has now started following the UK approval of the first COVID-19 vaccine on the 2 December. The government recommends that people who are at higher risks of becoming seriously ill due to COVID-19 should have the vaccine when it is offered to them, which includes people affected by lymphoma.

We are delighted with the success of our first ever Virtual Santa Run, and want to say a big thank you to everyone who took part in support of our work.

Venetoclax plus obinituzumab is now available on the NHS throughout the UK for people with CLL who have not been treated before.

People are recommended to take vitamin D supplements during autumn and winter. In England clinically extremely vulnerable people can register for a free 4-month supply.  

Tazemetostat, the first in a new class of drugs, shows promising efficacy and a favourable safety profile in people with relapsed or refractory follicular lymphoma.

We understand how difficult it can be to pick up the phone when you are worried about something. 

Updated guidelines give recommendations for treatment of people with Waldenström’s macroglobulinaemia.

The UK report provides an insight into the impact of treatment and care for people living with lymphoma. 
Read the UK report

New report finds two thirds of blood cancer patients are concerned about accessing the most effective treatment.

Charities urge Governments to minimise the impact of COVID-19 for people living with cancer.